Related Experiment Videos
Technetium-99m sestamibi myocardial tomography based on dipyridamole echocardiography testing in hypertensive
O Schillaci1, C Moroni, F Scopinaro
1Section of Nuclear Medicine, Department of Experimental Medicine and Pathology, University "La Sapienza", Rome, Italy.
Insights
Technetium-99m sestamibi tomography effectively diagnoses coronary artery disease in hypertensive patients with chest pain. A negative scan suggests no significant epicardial disease, while a positive scan may indicate epicardial or small-vessel disease.
Area of Science:
- Cardiology
- Nuclear Medicine
- Diagnostic Imaging
Background:
- Non-invasive diagnosis of coronary artery disease (CAD) in hypertensive patients with chest pain presents challenges due to limitations of exercise-dependent tests.
- Dipyridamole echocardiography shows comparable feasibility and accuracy in both hypertensive and normotensive individuals.
- Hypertension is a significant risk factor for CAD, necessitating reliable diagnostic tools.
Purpose of the Study:
- To evaluate the diagnostic capability of technetium-99m sestamibi tomography combined with dipyridamole echocardiography in hypertensive patients presenting with chest pain.
- To compare the diagnostic accuracy of this combined approach against coronary angiography, exercise electrocardiography, and dipyridamole echocardiography.
- To assess the utility of dipyridamole technetium-99m sestamibi imaging in differentiating epicardial CAD from small-vessel disease in this population.
Main Methods:
- Forty hypertensive patients with chest pain underwent technetium-99m sestamibi tomography (rest and dipyridamole stress) and exercise electrocardiography.
- Coronary angiography was performed to categorize patients into those with significant epicardial CAD (Group A, n=22) and those with normal coronary vessels (Group B, n=18).
- Dipyridamole echocardiography was also conducted for comparison.
Main Results:
- Dipyridamole technetium-99m sestamibi imaging demonstrated high sensitivity, correctly identifying 21/22 patients with epicardial CAD and showing positive results in 5/18 patients without significant epicardial disease.
- Dipyridamole echocardiography showed positive results in 18/22 patients with CAD and 5/18 without.
- Exercise electrocardiography had lower sensitivity, positive in 15/22 patients with CAD and 11/18 without, suggesting potential for false positives in hypertensive patients.
Conclusions:
- A negative dipyridamole technetium-99m sestamibi tomography scan effectively rules out significant epicardial CAD in hypertensive patients with chest pain.
- A positive scan may indicate either epicardial CAD or small-vessel disease, necessitating further evaluation.
- Combining technetium-99m sestamibi tomography with dipyridamole echocardiography allows for a comprehensive assessment of myocardial perfusion and contractile function under pharmacological stress.
Abstract:
The non-invasive diagnosis of coronary artery disease in hypertensives with chest pain is an important clinical concern because all exercise-dependent tests display limited feasibility and diagnostic accuracy; by contrast, dipyridamole echocardiography testing has been shown to have a similar feasibility and accuracy in hypertensive and normotensive subjects. The aim of this study was to evaluate the diagnostic capability of technetium-99m sestamibi tomography based on dipyridamole echocardiography testing in hypertensives with chest pain, and to compare the scintigraphic results with those of coronary angiography, exercise electrocardiography and dipyridamole echocardiography. Forty subjects with mild to moderate hypertension, chest pain and no previous myocardial infarction were submitted to 99mTc-sestamibi tomography (at rest and after high-dose dipyridamole echocardiography) and to exercise electrocardiography testing. At coronary angiography 22 patients (group A) had significant epicardial coronary artery disease (>/=70% stenosis of at least one major vessel) and 18 normal main coronary vessels (group B). Dipyridamole 99mTc-sestamibi imaging was positive in 21/22 patients of group A and in 5/18 of group B. Dipyridamole echocardiography was positive in 18/22 patients of group A and in 5/18 of group B. Exercise electrocardiography was positive in 15/22 patients of group A and in 11/18 of group B. Four out of five subjects in group B with positive results in all the tests showed a slow run-off of angiographic contrast medium, probably due to small-vessel disease. Significant epicardial coronary artery disease in hypertensives with chest pain is unlikely when dipyridamole 99mTc-sestamibi tomography is negative. When scintigraphy is positive, either epicardial coronary artery disease or a small-vessel disease condition is possible. The association of scintigraphy with dipyridamole echocardiography testing allows the assessment of contractile function and myocardial perfusion by a single pharmacological stress.